May 29, 2020 — Santa Monica, CA — CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announces an article discussing Israel’s recent approval for cannabis exports and how companies like Isracann Biosciences, Inc. (CSE: IPOT) (OTC: ISCNF) are well-positioned to profit.

Israel gave final approval in mid-May for exports of medical cannabis, paving the way for more than one billion shekels ($273 million) in annual revenue. The country will become one of just three countries that have approved the export of medical cannabis to countries that permit its use—after Canada and the Netherlands— when the law goes into effect on June 13, 2020.

With its favorable climate and expertise in medical and agricultural technologies, Israel could become one of the world’s biggest producers of medical cannabis. iCAN estimates the global market for Israel’s medical cannabis could be as high as $33 billion, while Israeli companies like Syqe Medical have pioneered innovative medical cannabis technologies.

The go-ahead to export medical cannabis could open the door to new investment in the country, while existing Israeli producers, like Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF), could be well-positioned to benefit from near-term export demand.

Click Here To Receive Isracann’s Investor Presentation 

Let’s take a look at who stands to profit from the recent export decision and how investors can position themselves to capitalize on the developments.

Who Stands to Profit?

There are more than ten farms and five factories in Israel that meet the Health Ministry’s standards for medical cannabis exports, and several of them have already reached agreements to sell cannabis to Europe or Canada when licenses become available.

Isracann Biosciences Inc. (CSE: IPOT) (OTCQB: ISCNF) is Israel’s first pure-play cannabis firm wholly focused on becoming the nation’s premier, low-cost cannabis producer. The company has a joint venture agreement in place with a built 55,000 sq. ft. farm that’s expandable to 110,000 sq. ft. in the near-term and has access to over two million sq. ft. of private land.

“Our Hefer Valley farm is making great strides,” said Isracann’s VP of Operations, Matt Chatterton in a recent press release. “We engaged a specialist Israeli consultant to advance the certification of farm to EU-GMP standards thereby paving the way for our export distribution. In addition, the related post-harvest export facility is nearing readiness.”

In addition to its production, Isracann entered into a MOU earlier this year to distribute cannabis throughout European end markets. The distributor will import products through the Republic of Malta, subject to compliance and regulations, and is currently preparing a regional processing facility designed to meet EU-GMP standards.

Breath of Life International Ltd. planned to raise C$150 million on the Toronto Stock Exchange (TSE) through a public share offering priced at C$27 to C$32 per share last year, but management shelved plans for an IPO until market conditions improved in October 2019. The company reported $1.1 million in revenue during the first quarter of 2019 from the Israeli market.

Click here to view an exclusive interview with Isracann’s CEO Darryl Jones:

Click Here To Receive Isracann’s Investor Presentation 

Other Israeli cannabis producers that could benefit include:

• Cronos Group Inc. (TSX: CRON) has a strategic joint venture with Kibbutz Gan Shmuel, a commercial farming community, whereby it plans to build a 45,000 sq. ft. greenhouse in Israel that will help supply the European market.
• Aura Health Inc. CSE: BUZZ) holds convertible debt that converts to a 54% equity position in HolyCanna, a cultivation and nursery license in Israel. The company also signed a LOI with CannabiSendak to build a high-profile dispensary in Tel Aviv.
• Namaste Technologies Inc. (TSX-V: N) owns a 10% stake in Cannbit, a licensed cannabis operation in Israel. The company also has a collaboration and supply agreement with the company to purchase medical cannabis.

What’s Next for Israel?

Israel’s move to legalize medical cannabis exports could be transformative for many public and private companies operating in the country. Investors looking for exposure to the space may want to consider Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) as one of the only pure-plays in the space or a handful of other companies that have exposure through joint ventures and investments.

Learn more about Isracann Biosciences by downloading their investor presentation or visiting their website.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations.

THC BioMed Intl Ltd. (CSE: THC) recently recorded its second consecutive quarter of profitability along with more than $1 million in revenue. This represents profits of $88,191 for the three months ended January 31, 2020. Investors looking for exposure to the cannabis industry may want to take a closer look at the stock as an alternative to companies with high cash burn rates and losses in operations.

Click Here To Receive Updates on THC BioMed

Growing Revenue & Outlook

THC BioMed generated more than $1 million in revenue during the first two quarters of fiscal year 2020 with an average selling price of $4.20 per gram to medical patients and recreational buyers, including the Ontario Cannabis Store and BCcannabisonline. During the second quarter alone, revenue rose 163% year-over-year to $1,246,625.

“Over the last year, we have completed and started using new grow rooms to increase our output,” said President & CEO John Miller. “Our focus on high-quality, indoor-grown cannabis at reasonable prices has made our cannabis a best seller.”

The company achieved several key operational milestones over the past six months:

Sales of THC Kiss began on April 10, 2020. The cannabis beverage can be purchased by THC BioMed’s medical patients via the company’s online store.
Pure Cannabis Sticks — or filtered, paper cylinder pre-rolls — went into automated production.
A new three-year lease was signed for a property adjacent to the company’s production facility, which will be used to free up space for more production.
Its Cannabis Act license was amended to include the production and sale of cannabis edibles, topicals and extracts, opening the door to new markets.

Management believes that these operational milestones pave the way for revenue growth over the coming quarters. In particular, the launch of Cannabis 3.0 products will expand the company’s addressable market, while the production efficiencies offered by Pure Cannabis Sticks boost bottom line performance.

Click Here To Receive Updates on THC BioMed

Sustainable Profitability

THC BioMed reported net income of $88,191, gross profit before fair value adjustments of $759,959, and adjusted EBITDA of $131,549 during the second quarter, representing its second consecutive quarter of profitability—a rarity among licensed producers that have historically experienced a high cash burn rate.

Second quarter net income was lower than the $688,925 reported during the first quarter on the surface, but gross profit before fair value adjustments and adjusted EBITDA were higher than first quarter levels of $295,480 and $890, respectively. These figures suggest that the actual bottom line performance has improved quarter over quarter.

“We are proud to have achieved our second consecutive profitable quarter,” added Mr. Miller. “Our financial statements for Q2 2020 reflect the improvements we have realized in all key indicators of economic progress.”

It’s worth noting that the average price of $4.20 per gram is lower than the average prices reported for other licensed producers, which makes the profitability even more significant, as margins are lower than the competition. If industry average prices trend lower, the company doesn’t have to cut its prices in order to remain competitive.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few profitable licensed producers in the industry, giving them an edge over other companies that are reliant on potentially dilutive future fundraising to stay alive.

Click Here To Receive Updates on THC BioMed

Click here to read the full feature: https://bit.ly/2V2r0Se

THC BioMed Contact:
CEO: John Miller
[email protected]
844-842-6337

CFN Media Contact:

President Frank Lane
[email protected]
206-369-7050

About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis, CBD & Psychedelic industries.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product offerings, staffed by expert sales associates ready to educate consumers on the value of their products. In short, every brand would like its own version of the Apple Store or the Gap. Of course, every brand can’t afford to develop its own store, and cannabis licensing requirements often make the idea even more untenable.

CalEthos may have the answer for cannabis brands struggling to solve this problem. The company is currently financing the first of several planned cannabis superstores, appropriately called SHOWCASE, in Southern California. The concept is to provide partner cannabis brands their own space within a 20,000 sq. ft. SHOWCASE footprint, allowing them to fully display all that a brand has to offer. Each SHOWCASE location will also feature a medical pharmacy, an event center for community and consumer education, and a cafe and lounge areas to enhance the consumer experience and extend the shopper’s stay. Rather than the cramped, hurried environment common throughout retail cannabis, SHOWCASE promises to cater to both the customer and the brand in an elevated, inviting space.

CalEthos President Piers Cooper sat down with CFN Media to discuss the ideal setting for retailers to SHOWCASE their cannabis brand. Please click on the video below for the full story.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

Click below to hear CalEthos’ President Piers Cooper discuss the SHOWCASE concept

CalEthos Did the Homework

The two executives largely responsible for the CalEthos concept, CEO Michael Campbell and President Piers Cooper, have a long history in advising, building, and investing in companies both private and public. They kept bumping up against the emerging cannabis industry and decided to investigate, looking for opportunities arising from shortcomings in the young marketplace. They settled on retail, visiting a wide variety of stores and brands and talking to everyone involved, from the consumer to the staff to the product companies.

These investigations highlighted the problems listed above, both for the brand and for the consumer. Cannabis has been legalized, but many stores still carry a bit of a black-market vibe which is uninviting to newer cannabis consumers. Space is at a premium, as most dispensaries don’t have the capital to build large format stores or expand and upgrade existing stores. Budtenders are generally helpful, but they are usually limited to some personal advice about a brand they like before making the sale and moving on to the next in line.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

From the brand side, it is almost impossible to build a loyal customer base under such conditions. With advertising options limited, brands don’t have anywhere to turn. A given dispensary may carry 5 out of the brand’s 50 SKUs, whilst those 5 products are generally displayed amongst many other brands with limited space or capability for differentiation.

Campbell and Cooper came away from their research knowing there had to be a solution that provided a better consumer experience while enabling product makers to actively engage and educate those consumers.

Click below to hear CalEthos’ President Piers Cooper discuss The SHOWCASE Model Inspiration

The SHOWCASE Solution

CalEthos enlisted the help of Stephen Brady, the man responsible for the design of numerous Ralph Lauren, Bloomingdales, Gap, Old Navy, Banana Republic and other retail stores. Brady helped them realize the vision of an open, engaging, vital retail setting in which consumers are given space and options and educational opportunities. CalEthos is tuned in to the need to invite and educate ‘canna-curious’ consumers, and the SHOWCASE design enables that with event and education space along with lounge areas and a cafe. The concept is not turn and burn, though there is nothing stopping a customer from grabbing what they need and leaving quickly. Rather, the concept is explore and learn and enjoy. CalEthos believes consumers will gravitate to its model over the typical marijuana dispensary in the Southern California market.

Rendering of CalEthos SHOWCASE retail store

The company already knows that brands will appreciate the opportunity to create their own stores-within-a-store. Brand partners can procure dedicated space under the SHOWCASE Brand Membership Program that ranges from a 10’ x 16’ boutique with 90’ of shelf space, to shared kiosks in specialty product sections with 21’ of shelf space per brand, to 18’ of refrigerated shelf space in the Chill Zone for edibles and beverages. The SHOWCASE design also features a pharmacy dedicated to medicinal cannabis products and to provide advice for consumers exploring alternative medical options offered by cannabis products. All spaces are staffed by associates who are highly trained on products sold in their display areas.

Ready to SHOWCASE your Brand? Click Here to Apply.

Click below to hear CalEthos’ President Piers Cooper discuss the CalEthos Event Center

Overall, the concept is compelling and a refreshing change from the typical dispensary environment. Southern California, with its advanced legal market, huge population, and trend-setting reputation, is a prime location for the SHOWCASE concept. Investors interested in learning more about the opportunity are encouraged to follow the links. The future of cannabis retail awaits.

For Additional Information on CalEthos Please Visit the website at: https://www.calethos.com

CalEthos

CEO Michael Campbell

[email protected]

714-352-5315

CFN Enterprises

President Frank Lane

206-369-7050

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry. 

In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market. 

Click below to view more on Isracann Biosciences  – Israel’s First Pure Play Cannabis Firm

BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”

Click Here To Receive Isracann’s Investor Presentation 

The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.

This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade. 

While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.

The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.

In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.). 

Click Here To Receive Isracann’s Investor Presentation 

Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones on Israel as a Cannabis Investment

Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones on How Israel became the Cannabis Research Capital of the World

The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.

Click Here To Receive Isracann’s Investor Presentation

Click Here to Stay Up to Date with CFN Media, Your Premier Destination for Cannabis, CBD &  Psychedelic Financial Media

Isracann Biosciences Contact:

Investor Relations

Toll Free: +1 855.205.0266

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

• Corporate positions decreased by approximately 33% and operational positions decreased by approximately 13%
• Total number of positions decreased by approximately 15% across the Company
• New structure focuses the business on accelerating revenue growth in the Canadian market

TORONTO, February 11, 2020 – The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced the implementation of a new operating structure, including staff reductions, to drive efficiencies and support long-term, profitable growth.

As previously announced on January 6, 2020, Supreme Cannabis’ board and management team are focused on achieving greater efficiencies and speed to market by rightsizing production, overhead and capital expenditures. At a corporate, operational and international level, the Company’s management team is focusing its businesses and implementing new operating models that prioritize near-term revenue growth in the Canadian market.

“As Interim President and CEO, I committed to take immediate steps to position Supreme Cannabis for long-term success, including rightsizing the Company’s cost structure and focusing our efforts on near-term revenue-generating opportunities,” said Colin Moore, Director and Interim President and CEO. “Recent staff reductions were an extremely difficult decision for myself and the Board, but I believe them to be necessary to create a more agile, focused and profitable organization for the long-term benefit of all of Supreme Cannabis’ stakeholders. The changes we are implementing will empower our people, drive value for our shareholders and ensure that we continue to deliver a consistent and premium product to our consumers.”

Under the new optimized organization, reporting structures at the corporate level are being streamlined and vendor contracts and support services have been rationalized. Focusing the Company on near-term revenue generating opportunities and creating a more nimble and effective corporate structure resulted in a 33% reduction in employee headcount at a corporate level. In addition to ongoing improvements to the Company’s operational efficiencies, Supreme Cannabis has begun implementing a flatter organizational structure and cost-saving measures across its operating assets, including a reduction in the number of positions at the operational level of approximately 13%. Across the Company, the total number of positions have decreased by approximately 15%.

As part of management’s enhanced focus on domestic operations and prioritizing near-term profitability, the Company exited its investment in Supreme Heights, its UK and European cannabis investment platform, by exercising its retractable rights to return all investments back to the Company. Supreme Cannabis will continue to achieve capital-light, international exposure to the global wellness and medical markets through its Truverra business and MG Health Lesotho investment.

As previously announced, the Company will provide its second quarter financial results for the three and six months ended December 31, 2019, as well as an update on its plan for accelerated revenue growth and strategy to support its transition into a premium cannabis CPG company, after markets close on February 13, 2020.

About Supreme Cannabis.

The Supreme Cannabis Company, Inc., (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), is a global diversified portfolio of distinct cannabis companies, products and brands. Since 2014, the Company has emerged as one of the world’s fastest-growing, premium plant-driven lifestyle companies. Supreme Cannabis’ portfolio of brands caters to diverse consumer experiences, with brands and products that address recreational, wellness, medicinal and new consumer preferences.

The Company’s brand portfolio includes, 7ACRES, Blissco, Truverra, Sugarleaf by 7AC and Khalifa Kush Enterprises Canada. Supreme Cannabis’ brands are backed by a focused suite of world-class operating assets that serve key functions in the value chain, including, scaled cultivation, value-add processing, centralized manufacturing and product testing and R&D. Follow the Company on Instagram, Twitter, Facebook, LinkedIn and YouTube.

We simply grow better.

Forward-Looking Information.

Certain statements made in this press release may constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking information may relate to anticipated events or results including, but not limited to: the ability to drive shareholder value; continuing to deliver a consistent and premium product to consumers; winding down its investment in Supreme Heights; continuing to achieve capital-light international exposure to the global wellness and medical markets; and other statements that are not historical facts. Particularly, information regarding our expectations of future results, targets, performance achievements, prospects or opportunities is forward-looking information. Often, but not always, forward-looking information can be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “plan”, “could”, “should”, “would”, “outlook”, “forecast”, “anticipate”, “foresee”, “continue” or the negative of these terms or variations of them or similar terminology. Forward-looking information is current as of the date it is made and is based on reasonable estimates and assumptions made by us at the relevant time in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. However, we do not undertake to update any such forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws in Canada. There can be no assurance that such estimates and assumptions will prove to be correct. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking information, including, without limitation, the factors discussed in the “Risk Factors” section of the Company’s Annual Information Form dated September 17, 2019 (“AIF”). A copy of the AIF and the Company’s other publicly filed documents can be accessed under the Company’s profile on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. The Company cautions that the list of risk factors and uncertainties described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information.

SOURCE The Supreme Cannabis Company, Inc.

More Information.

Madelin Daviau, Investor Relations
Email: [email protected]
Phone: 416-466-6265
supreme.ca

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Colorado cannabis sales hit $1 billion in total cannabis-related revenue in 2019, becoming the first state in the country to hit that milestone five years after legalization. In addition, Colorado has the highest per-person spending on cannabis at $280 per year, which is significantly higher than the $220 and $130 annual spend in Washington State and Oregon, respectively.

General Cannabis Corp. (OTCQX: CANN) recently signed a purchase agreement to acquire SevenFive Farms, a cultivation facility in Boulder, Colorado, to expand its operations into the state, marking another step towards building a network of mature cannabis business across Colorado, California, and eventually, Oregon.

Click here to receive an investor deck and corporate updates

Building a Foundation

SevenFive Farms operates a 17,000 sq. ft. light deprivation greenhouse cultivation facility that has been in place for over four years. Boulder is strategically located along the Front Range where it has easy access to Denver, Colorado Springs, Fort Collins and other major metro markets, as well as an easy path to mountain towns that draw tourists.

General Cannabis expects to improve production at the facility to approximately 300 pounds of flower per month, which could generate over $5 million in annual revenue and $3 million in positive contribution towards EBITDA. The product will be sold primarily to the wholesale market until the company adds retail operations to its larger business.

“This acquisition represents another step in executing our Cannabis 3.0 strategy,” says CEO Steve Gutterman. “We are acquiring a proven, successful facility. We will deploy Next Big Crop, our cultivation consulting business, to improve production over existing levels. And we will use the production from the facility to supply dispensaries as we add them.”

The all stock acquisition is pending approval from the Colorado state regulators (MED) and will close when the approval process is complete.

Click here to receive an investor deck and corporate updates

Cannabis 3.0 Approach

General Cannabis aims to capitalize on “second-mover advantage” by cherry-picking assets in mature markets and allocating capital efficiently and effectively to produce outsized returns. Rather than taking execution risk and starting from scratch, the company applies the expertise of its diverse team to find mature opportunities with lesser risk.

Prior to the purchase agreement with SevenFive Farms, the company announced a letter of intent to acquire Hälsa Holdings Inc., which has purchase agreements or letters of intent with three retail dispensaries in California. The acquisition will also add Chris Colón to the executive team, bringing a wealth of operational experience.

“We have painstakingly picked out marquee assets in California,” said President Chris Colón. “The assets we have under contract are excellent revenue-producing stores with extraordinary possibilities for expansion.”

Investors could see similar acquisitions over the coming quarters focused on mature opportunities in California, Colorado and Oregon where it can apply its expertise to expand revenue, improve profitability and ultimately add tangible EBITDA to its bottom line for shareholders.

Click the image to watch an exclusive interview with General Cannabis CEO Steve Gutterman and Hälsa Holdings CEO Chris Colón

Click here to receive an investor deck and corporate updates

Looking Ahead

With the pending Hälsa and SevenFive Farm acquisitions, General Cannabis Corp. (OTCQX: CANN)  is executing on the Cannabis 3.0 strategy. The company is focusing on profitability and smart growth, and investors may want to take a closer look at the stock over the coming quarters as it grows its operational footprint in key U.S. markets.

For more information, visit the company’s website or sign up to download their investor presentation and receive corporate updates.

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Many expect 2020 to go down as the shakeout year for the Canadian cannabis industry; the year where winners will make their way to the top and companies with weak fundamentals will be ruled out. Of the potential winners, The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) is one Canadian player that stands out with its simple yet differentiated approach,  strong core business and focused growth drivers. 

In 2019, the company built the infrastructure, developed the brands and attracted the people necessary to establish a winning Canadian cannabis business. In 2020, a few key drivers are accelerating the company forward and setting it apart from other players in the space: 

1. Realizing scaled efficiencies with construction on flagship facility complete 
2. Transitioning to a high-margin CPG business with consumer-facing brands 
3. Gaining recreational market share with new brands and product formats 
4. Delivering 2.0 products that showcase high-quality cannabis inputs 
5. Relying on a proven team from operations to the c-suite

1. Realizing scaled efficiencies with construction on flagship facility complete 

With the completion of the company’s flagship 7ACRES facility in Kincardine, Ontario, Supreme Cannabis joins the small list of licensed producers with fully built-out operating assets and is first on the list of producers with a scaled cultivation asset capable of producing premium cannabis. 

This 440,000 square foot facility includes administrative areas, processing space and of course almost 250,000 square feet of cultivation space. In order to maintain a premium product, the company takes a small-batch approach to cultivation, growing in rooms no larger than 10,000 square feet, completing a full plant 2-week dry, and finishing the cannabis with a hand-trim.  

With construction complete, 7ACRES has the ability to maintain its premium practices while truly benefitting from scale; operating at scale brings about production efficiencies, increases the number of harvests per week and allows for greater automation and other advancements that help both top and bottom lines.

From the beginning, the company aimed to build meaningful square feet, not the most square feet. As the industry enters into an anticipated period of oversupply, Supreme Cannabis’ approach to premium cultivation is more important than ever. 7ACRES’ differentiated high-end product makes the company less susceptible to the pricing pressures the industry is facing.  

2. Transitioning to a high-margin CPG business with consumer-facing brands 

With construction complete, Supreme Cannabis also gains additional packaging capacity at the 7ACRES facility. Since inception, packaging constraints have left 7ACRES dependent on making bulk wholesale sales to other licensed producers. With a desirable premium product, strong consumer brands and greater packaging capacity online, Supreme Cannabis is now able to transition to 100% consumer-facing sales and capture more attractive recreational margins.

With 100% consumer-facing sales expected by the company’s fiscal Q3 (January 2020 to March 2020), management is on track to transform Supreme Cannabis from a wholesale supplier to a consumer packaged goods (CPG) company. There is nothing subtle about the change and the increased capacity, as the integration allows 7ACRES to sell all products into the lucrative recreational market directly to retailers that currently are having difficulty keeping popular – and award winning – 7ACRES products in stock.

After recently inking deals to supply retailers in Quebec and Newfoundland and Labrador, 7ACRES products are now available throughout all of Canada. With additional distribution opportunities, the company intends to install two new bottling lines at the facility during the current fiscal year (which runs through to June 2020), further increasing 7ACRES’ output.

3. Gaining recreational market share with new brands and product formats 

In July 2019, Supreme Cannabis closed the acquisition of wellness cannabis brand Blissco. The company subsequently installed a large-scale ethanol extraction system in addition to the existing CO2-based extraction system Blissco was operating in British Columbia. Blissco is forecasted to have the capacity to produce 7 million tincture bottles annually.

In the first half of the calendar year (H2 of Supreme’s fiscal year), the company will begin to realize the benefits of these additional operations and new products coming online. Blissco recently launched a new full-spectrum CBD (cannabidiol) oil branded Pūr Dew. Supreme Cannabis also introduced Sugarleaf by 7AC, offering a new product format and brand for consumers seeking more convenient and accessible cannabis experiences.  

4. Delivering 2.0 products that showcase high-quality cannabis inputs 

Also upcoming – the company expects to benefit from a full quarter of 2.0 product sales by Q4 fiscal 2020 (May-June). The first 2.0 product to market will be from a partnership struck last summer with vaporizer company Pax Labs, a market leader with over 1.5 million devices sold worldwide. Pax was proactive in penning  agreements with select producers ahead of Cannabis 2.0. In October 2019, Canada amended its cannabis regulations, allowing new products, including vaporizers, but with requisite product approvals the market is only just getting off the ground. 

Through its agreement with PAX, 7ACRES is one of only four licensed producers chosen as initial partners to create cannabis oil pods for the PAX Era. Supreme Cannabis is in good company, other initial partners include: Aurora Cannabis Inc. (TSX: ACB) (NYSE: ACB), Aphria Inc. (TSX: APHA) (NYSE: APHA) and Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI). 

5. Relying on a proven team from operations to the c-suite 

As Supreme Cannabis and the rest of the cannabis industry mature, attracting top talent is of the utmost importance. Supreme Cannabis’ appeal and potential is clearly illustrated by the types of leaders it is attracting at every level. Most recently, John Griese joined the company as Chief Operating Office. This executive has held senior level positions in operations and supply chain with Nestle and Pepsico. In addition to John, Joel Toguri recently joined Supreme Cannabis as SVP Commercial, Joel brings over 20 years of regulated industry knowledge from both the cannabis and alcohol and beverage space. 

To achieve its vision of operating as a CPG company, Supreme has clearly been building out a strong management team, bringing in seasoned vets with success in the CPG business. On January 6, the company announced the departure of CEO Navdeep Dhaliwal and appointed Colin Moore, Supreme Cannabis director and former President of Starbucks Coffee Canada as Interim President and CEO. Moore will guide the ship while the board conducts a search to hire a new CEO to with the background to succeed in its mission for profitable, long-term growth. In the interim, there are few people better positioned than Mr. Moore to take on the role of CEO. Colin has 40 years of experience driving growth and efficiencies in consumer businesses like Starbucks, as well as deep familiarity with the Company and management team as a Board director.

Supreme Cannabis trades as FIRE on the Toronto Stock Exchange (TSX: FIRE), SPRWF on the OTC Exchange in the United States (OTCQX: SPRWF) and 53S1 on the Frankfurt Stock Exchange (FRA: 53S1). Follow Supreme on Instagram, Twitter, Facebook and YouTube.

Click here to receive a Supreme Cannabis Investor Deck and Corporate Updates

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Canada’s cannabis sector has experienced a sharp sell-off over the past year, with the Marijuana Index’s Canadian Index moving from a high of $727 in March to a low of $196 in November. Rather than looking solely at growth in production capacity, many investors are shifting their focus to tangible revenue growth and profitability. Profitable licensed producers can be more selective in raising capital — limiting dilution — and generate tangible shareholder value — in the form of retained earnings.

THC BioMed Intl Ltd. (CSE: THC) (OTXQX: THCBF) (“THC BioMed”) is one of the few licensed producers that has managed to turn a profit as it broke $1 million in revenue last quarter. In addition to ramping up output, the British Columbia-based grower cited its premium cannabis and reasonable prices for helping it become a bestseller among consumers. Management’s long experience in the space — moving from Exemption 56 to ACMPR license to the Cannabis Act — has taught them how to grow great medical & recreational cannabis with unparalleled compliance.

In this article, we will take a closer look at THC BioMed’s strong quarterly performance and what catalysts investors can look forward to ahead.

Click Here To Receive Updates on THC BioMed 

Robust Growth & Profitability

THC BioMed reported revenue that rose about 275% year-over-year to $1,044,510, during the quarter ended October 31, 2019, with an average selling price of $4.20 per gram to medical patients and recreational buyers, such as the Ontario Cannabis Store and BC Cannabis Stores. These prices are much less than the $5.00 or more reported by other licensed producers, according to data from Cannabis Benchmarks. Lower production costs could enable the company to capture market share right now, as well as provide a buffer if cannabis prices continue to fall.

Average Cost of Production for LPs – Source: Cannabis Benchmarks

On the bottom line, the company’s adjusted EBITDA swung from a loss of $345,754 to a gain of $890 after accounting for changes in the fair value of cannabis inventory, share-based compensation and other non-operational factors. Many cannabis investors are seeking out companies with profitable operations since they can be more selective when raising capital, which potentially translates to less dilution for existing shareholders and easier access to capital required to grow the business over the long-term.

On the balance sheet, the company reported $6,301,916 in total assets versus $4,188,603 in total liabilities, yielding $2,113,313 in shareholders’ equity. Many licensed producers have struggled under debt hangovers after ramping up production capacity over the past couple of years. As the market matures, companies with less debt have less of a drain on cash flow and more flexibility when it comes to capitalizing on any new opportunities that may arise. Positive net asset levels could also provide shareholders with a buffer in their valuations.

Many Irons in the Fire

THC BioMed has prudently grown its business over the past several years, but that doesn’t mean that it’s not pursuing high-growth opportunities. Last quarter, the company amended its license to include the production and sale of cannabis edibles, topicals and extracts and submitted a new product application to Health Canada for Pure Cannabis Sticks — pre-rolls that are filtered, paper cylinders filled with pure cannabis to be manufactured using its automated production machine — dramatically lowering labor costs.

In addition, the company announced an alternative, brand new cannabis beverage product, THC Kiss, and submitted a new product application to Health Canada shortly after the quarter ended. Zion Market Research projects that the global market for cannabis beverages hit $1.6 billion in 2018 and could reach $4.46 billion by 2025, representing a 15.6% compound annual growth rate. The market is growing so quickly that many traditional beverage companies, such as Constellation Brands Inc. (STZ), have made significant investments into cannabis.

Finally, the company acquired an additional strata lot at its production facility to increase grow capacity. Management’s unique approach to growing cannabis also ensures the highest-quality products reach consumers — from selecting only the best feminized seeds to hand-trimming at the perfect time and placing product on drying racks to dry and cure over an extended period of time. The combination of low-cost production methods and experience growing premium cannabis creates an easy bestseller.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few licensed producers that have achieved profitability on the bottom line. As the market shifts their portfolios from growth to value, investors may want to keep an eye on the company that has prudent financial discipline and plenty of potential catalysts ahead. It’s long track record shows that management has been able to balance these objectives and deliver shareholder value with an eye for creating low-cost, high-value products for consumers.

Click Here To Receive Updates on THC BioMed 

To Learn more about THC BioMed (CSE: THC) (OTCQX: THCBF) visit the Company’s Website: https://thcbiomed.com

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

There is no country on Earth that has a history steeped in cannabis research like that of Israel. Furthermore, there is no government that is more supportive of medical marijuana research than Israel. Yet, the small country has by and large gone overlooked for what it has to offer as an investment opportunity. That is until recently.

“[Israel has] broken down the barriers,” said Darryl Jones, CEO of Isracann Biosciences (CSE: IPOT) (OTC: ISCNF), in a Q&A session with CFN Media. “It’s flown under the radar for a while, but a lot of people are starting to come around and realize that Israel is a cannabis hub.”

Isracann, the first pure-play cannabis firm in Israel to list in Canada and U.S., is 100% focused on building out its fully-funded, 230,000 square-foot facility in the southern part of Israel. Isracann is working directly with Israeli Ministries and collaborating with a team of top lawyers and consultants to move the project expeditiously forward while staying on side with all regulatory processes. The company recently expanded in cultivation capacity through a new joint venture west of Be’er Sheva, Israel.

Click Here To Receive Isracann’s Investor Presentation

Birthplace of Cannabis Research

Dr. Raphael Mechoulam has rightfully earned the nickname the “Father of Marijuana Research.” More than 50 years ago, the Israeli organic chemist was the first person ever to isolate cannabidiol (CBD, a non-intoxicating compound in cannabis) and tetrahydrocannabinol (THC, the psychoactive component of cannabis). In the 1990’s, Dr. Mechoulam discovered that cannabinoids occur endogenously throughout the human body, making up the endocannabinoid system along with specific receptors.

Cannabinoids like CBD and THC, amongst more than 100 others, are compounds found in cannabis that act on cannabinoid receptors throughout the body, including the brain, nervous system, organs and tissue, to control a host of functions, such as pain management, the immune system, appetite and mood.

At 89 years of age, Dr. Mechoulam is still active in the cannabis space as a professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. His extensive body of work has earned him many awards, including a Lifetime Achievement Award at CannMed in 2016.

It is because of Dr. Mechoulam and his collaborators that scientists today are in the best position ever to understand regulation of the endocannabinoid system and what it can do for next-generation, cannabis-based medicines.

No Place Like It

Israel would not have its rich cannabis history if it weren’t for a supportive government. As discussed by Jones in the interview, Israel is the only country in the world where an organization can hold and independent research license and conduct studies on marijuana.

On top of friendly regulators, Mother Nature has blessed Israel with nearly perfect conditions for growing cannabis. Israel has 300+ days of sunshine each year, high UV rays and temperature and humidity that are ideal for growing the plant.

To that end, the country is highly regarded for its talent pool in agriculture and extensive infrastructure supportive of the industry.

This results in high-quality, low cost cannabis production.

Click Here To Receive Isracann’s Investor Presentation

Earlier this year, Israeli lawmakers passed legislation to allow for cannabis exports. That puts the country in elite company along with only the Netherlands and Canada as countries were cannabis exports are legal. It is expected that the framework will be in place to commence shipments in 2020.

According to Jones, the new laws will ultimately lead to Israeli technology and cannabis breaking into the European Union, getting into the hands of people that need and can benefit from it. In addition to serving the growing domestic market in Israel, Isracann has its sights set on Germany, the largest economy in the E.U. and one that has an emerging medical marijuana market.

Not Without Challenges

Jones has watched the cannabis industry in Canada unfold over the last couple decades, which brings experience to the up-and-coming market. To that point, he sees similarities between Israel and where Canada was 4-5 years ago. One of the biggest challenges for any emerging market is educating doctors and patients as to why cannabis can provide a therapeutic benefit.

Israelis are by no means completely unfamiliar with cannabis. In fact, the country has one of the highest per capita user rates in the world.

Currently, there are about 45,000 Israeli patients, with another 10,000 on a waiting list. The cannabis patient population is growing 10-15% annually, says Jones, which makes for a very attractive market opportunity immediately.

Click Here To Receive Isracann’s Investor Presentation

To learn more about Isracann Biosciences Click Here

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.